Gangagen

Executive Summary

GangaGen is an Indian biotechnology company at the preclinical stage, focused on developing novel endolysin-based therapies to combat multidrug-resistant bacterial infections. The company's platform engineers bacteriophage-derived proteins to precisely target and lyse Gram-positive and Gram-negative pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa. With the global rise of antimicrobial resistance, GangaGen's approach offers a promising alternative to conventional antibiotics. The company is headquartered in Bengaluru and was founded in 2020. Despite its early stage, GangaGen addresses a critical unmet need in infectious disease, positioning itself for potential partnerships and clinical advancement. Key milestones ahead include regulatory filings and initial clinical trials expected within the next 12-18 months.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data for Lead Endolysin Candidate65% success
• TBDSeries A or Grant Funding Announcement40% success
• TBDIND Filing or Phase 1 Trial Initiation30% success